Y
Yongqin Wan
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 7
Citations - 418
Yongqin Wan is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Smoothened & Hedgehog signaling pathway. The author has an hindex of 5, co-authored 7 publications receiving 380 citations.
Papers
More filters
Journal ArticleDOI
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Shifeng Pan,Xu Wu,Jiqing Jiang,Wenqi Gao,Yongqin Wan,Dai Cheng,Dong Han,Jun Liu,Nathan P. Englund,Yan Wang,Stefan Peukert,Karen Miller-Moslin,Jing Yuan,Ribo Guo,Melissa Matsumoto,Anthony Vattay,Yun Jiang,Jeffrey Tsao,Fangxian Sun,AnneMarie Culazzo Pferdekamper,Stephanie Kay Dodd,Tove Tuntland,Wieslawa Maniara,Joseph Kelleher,Yung-mae Yao,Markus Warmuth,Juliet Williams,Marion Dorsch +27 more
TL;DR: Structural-activity relationship studies led to the discovery of a potent and specific Smoothened antagonist N-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)biphenyl- 3-carboxamide (5m, NVP-LDE225), which is currently in clinical development.
Patent
Compounds and compositions as hedgehog pathway modulators
TL;DR: In this paper, a method for modulating the activity of the hedgehog signaling pathway was proposed, in which a cell with a sufficient amount of a compound of Formula I was contacted to prevent aberrant growth states.
Patent
Hedgehog pathway modulators
TL;DR: In this paper, a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway was proposed. In particular, the method provided a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of function, smoothened gain of function or GIi gain-ofthe-function.
Patent
Compounds and compositions as hedgehog signaling pathway modulators
TL;DR: In this article, a method for modulating the activity of the hedgehog signaling pathway was proposed, in which a cell with a sufficient amount of a compound of Formula I was contacted to prevent aberrant growth states.
Journal ArticleDOI
Design, synthesis, and structure-activity-relationship of phenyl imidazoles as potent Smoothened antagonists.
Dai Cheng,Dong Han,Wenqi Gao,Qihui Jing,Jiqing Jiang,Yongqin Wan,Nathan P. Englund,Tove Tuntland,Xu Wu,Shifeng Pan +9 more
TL;DR: Through scaffold morphing of a known Smoothened antagonist Antag691, a series of novel phenyl imidazole derivatives were developed and led to the discovery of potent, selective and orally bioavailable Smoothensed antagonist 19 that is suitable for in vivo studies.